Fluorescent detection of SignalSilence® Control siRNA (Fluorescein Conjugate) in living HeLa cells 24 hours post-transfection, demonstrating nearly 100% transfection efficiency. TransIT-TKO® Transfection Reagent from Mirus was used (Mirus catalog #MIR2114).
Western blot analysis of extracts from HeLa cells, either untransfected or transfected with NF-κB p65 siRNA #6261 or SignalSilence® Control siRNA (Fluorescein Conjugate), using NF-κB p65 Antibody #3034.
CST recommends transfection with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) 24 to 48 hours prior to cell lysis. For transfection procedure, follow protocol provided by transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 20 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 µl per well.
SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
RNA interference is a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. SignalSilence® Control siRNA (Fluorescein Conjugate) from Cell Signaling Technology (CST) is an siRNA sequence that will not lead to the specific degradation of any cellular message. It is intended to serve as a negative control for experiments using targeted siRNA transfection. In addition, this siRNA is fluorescein-conjugated to allow the researcher to assess transfection efficiency by fluorescence microscopy.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.